Document:

License Agreement

  
 Exhibit 10.2

 LICENSE AGREEMENT 
 This License Agreement is entered into and made effective as of July 28, 1997, by and among SciClone Pharmaceuticals, Inc., a California corporation, and SciClone Pharmaceuticals International, Ltd.,
a Cayman corporation (collectively “Licensee”), and Edward T. Wei, an individual (“Licensor”), with respect to the facts set forth below. 
 RECITALS 
 A. Licensee is engaged in development of medical products
which may be able to utilize the Licensed Technology (defined below). 
 B. By assignment, Licensor is the owner of, and
Licensor has the exclusive right to grant a license to, the Licensed Technology, except those patents or applications issued or filed in Russia Licensor has furnished to Licensee copies of the assignment documents for the Licensed Technology,
consisting of an Assignment and an Acknowledgment from the Russian Inventors (defined below) and an assignment from Verta Ltd. and Cytokin Ltd., each a Russian company (collectively the “Russian Companies”), who were the employers of the
Russian Inventors. 
 C. Licensor desires to grant to Licensee, and Licensee wishes to acquire, an exclusive worldwide
(excluding Russia) license to the Licensed Technology, subject to the terms and conditions set forth herein. The Licensed Technology is also known as the “Bestim” Technology. 

AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions set forth herein, Licensor and Licensee hereby agree as follows: 
 1. Definitions. Capitalized terms shall have the meaning set forth below. 

1.1. Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly controls, is controlled by or is
under common control with a party. The term “control” as used herein means the possession of the power to direct or cause the direction of the management and the policies of an entity, or person, whether through the ownership of a majority
of the outstanding voting securities or by contract or otherwise. 
 1.2. Combination Product. The term “Combination
Product” shall have the meaning as defined in Section 4.3.1 below. 
 1.3. Component Product. The term
“Component Product” shall have the meaning as defined in Section 4.4.1 below. 

  
 1.4. Composition of
Matter Patent Claims. The term “Composition of Matter Patent Claims” shall mean those certain patent claims which constitute composition of matter claims (other than method of use claims) within the Licensed Patents which are
eventually allowed by the applicable governmental patent office, from and after the date when a valid patent issues for said claims, if at all. If a valid patent so issues in one or more countries but not in other countries, then the Net Sales
realized from each such issuing country shall be treated as Net Sales realized from Composition of Matter Patent Claims. 
 1.5.
Confidential Information. The term “Confidential Information” shall mean any and all proprietary or confidential information of Licensor or Licensee which may be exchanged between the parties at any time and from time to time in
connection with this Agreement. Information shall not be considered confidential to the extent that it: 
 a. is publicly
disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; or 
 b. was
known to the receiving party prior to the date of disclosure, which knowledge was acquired independently and not from the other party hereto (or such party’s employees or agents); or 

c. is subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or

 d. has been published by a third party as a matter of right; or 

e. is developed or acquired totally independent from and with any benefit from any confidential information received from the disclosing
party. 
 1.6. Effective Date. The term “Effective Date” shall mean when all of the. following documents have
been executed by all of the parties thereto: (i) this Agreement, (ii) the Inventors’ Acknowledgment of Assignment, (iii) the Russian Companies’ Acknowledgment of Assignment, and (iv) the Research Funding Agreement.

 1.7. Inventors’ Acknowledgment of Assignment. The term “Inventors’ Acknowledgment of Assignment”
shall mean the document by that name approved by SciClone. 
 1.8. Licensed Patents. The term “Licensed
Patents” shall mean the patent rights described on Exhibit A attached hereto, plus all patents issued based on divisionals, continuations, continuations-in-part, reissues, re-examinations and extensions of the patent rights described in
paragraph 1 of Exhibit A, together with all corresponding foreign patents, except for those issuing in Russia, and together with all related pending patent applications and inventor’s certificates, and together with all patents and patent
applications covering improvements to the inventions described in the foregoing, filed or issued in any country, except in Russia. 
 1.9. Licensed Product. The term “Licensed Product(s)” shall mean any product or process which cannot be developed, manufactured, used or sold (i) without infringing on the valid
issued claims of the Licensed Patents, or (ii) without utilizing the Licensed Technology. 

  
 1.10. Licensed
Technology. The term “Licensed Technology” shall mean the Licensed Patents, plus all improvements thereto developed by Licensor, the Russian Companies or the Russian Inventors (defined below), and all data, studies, know-how,
technology, confidential information and other intellectual property rights belonging to Licensor, the Russian Companies or the Russian Inventors, which relate to the Licensed Patents or are conceived or reduced to practice by one or more of such
parties during the term of the Research Funding Agreement. 
 1.11. Licensed Territory. The term “Licensed
Territory” shall mean worldwide, except for Russia. 
 1.12. Method of Use Patent Claims. The term “Method of
Use Patent Claims” shall mean those certain patent claims within the Licensed Patents which are eventually allowed by the applicable governmental patent office, from and after the date when a valid patent issues for said claims, if at all. If a
valid patent so issues in one or more countries but not in other countries, then the Net Sales realized from each such issuing country shall be treated as Net Sales realized from Method of Use Patent Claims. 

1.13. Net Sales. The term “Net Sales” shall mean the gross amount received by Licensee, or its Affiliates and
sublicensees, or any of them, on sales to first customers of Licensed Products for therapeutic use after deducting (i) discounts actually given, (ii) credits for claims, allowances, retroactive price reductions or returned goods,
(iii) transportation and insurance costs and (iv) sales taxes, value added taxes or other governmental charges paid in connection with sales of Licensed Products (but excluding what is commonly known as income taxes). For purposes of
determining Net Sales, a sale shall be deemed to have occurred when a Licensed Product is shipped for delivery and payment has been received for said shipment. Sales of Licensed Products by Licensee or its Affiliates or a sublicensee thereof to any
Affiliate or sublicensee which is a reseller thereof shall not be considered in the computation of Net Sales, and only the subsequent sales of such Licensed Products by Affiliates or sublicensees to unrelated parties shall be deemed Net Sales
hereunder. Sales of Licensed Products for research purposes, or for the purpose of conducting clinical trials necessary or desirable in connection with securing regulatory approval of any Licensed Product in the Licensed Territory, shall not be
considered in the computation of Net Sales. In the event that a Licensed Product is a Combination Product, then the Net Sales from said Licensed Product/Combination Product shall be determined in accordance with the formula set forth in
Section 4.3 below. In the event that a Licensed Product is a Component Product, then the Net Sales from said Licensed Product/Component Product shall be determined in accordance with the formula set forth in Section 4.4 below. 

1.14. PTO. The term “PTO” shall mean the United States Patent and Trademark Office. 

1.15. Research Funding Agreement. The term “Research Funding Agreement” shall mean the document by that name, as signed
by all of the parties thereto, including Licensee, Licensor and the Russian Companies, a signed copy of which has been furnished to Licensee. 

  
 1.16. Russian
Inventors. The term “Russian Inventors” shall mean the following named individuals, who were co-inventors or participants for the conception and development of the Licensed Technology: 

Alexander A. Kolobov 
 Andrey S. Simbirtsev 
 Sergey V. Kulikov 

Alexey N. Prusakov 
 Natalia M. Kalinina 
 Natalia V. Pigareva 

Alexander U. Kotov 
 Vladimir M. Shpen 
 Oleg A. Kaurov 

Sergey A. Ketlinsky 
 1.17. Russian Companies’ Acknowledgment of Assignment. The term “Russian Companies’ Acknowledgment of Assignment” shall mean the document by that name, as signed by the Russian
Companies, a signed copy of which has been furnished to Licensee. 
 1.18. Russia. The term “Russia” shall mean
the geographical territory now known as the country of Russia. 
 1.19. Specified Countries. The term “Specified
Countries” shall mean: 
 Australia 
 Belgium 
 Canada 

Denmark 
 France

 Germany 
 Japan 
 Netherlands 

Sweden 

Switzerland 

United Kingdom 

United States of America 
 2.
License Grants. 
 Licensor hereby grants to Licensee an exclusive license in the Licensed Territory to utilize the
Licensed Technology, to use, make, have made, sell, offer to sell, import and export all products and/or processes and/or services, with the full right to grant sublicenses, subject to the terms of this Agreement. 

  
 3. License Fee, Licensor’s
Past Patent Costs and Milestone Payments. 
 3.1. License Fee and Licensor’s Past Patent Costs. Within ten
(10) business days after the Effective Date, Licensee shall pay to Licensor a license fee of $47,500, plus $10,000 for reimbursement of Licensor’s past patent costs. 
 3.2. Milestone Payments. 
 3.2.1. Within ten (10) business days after
Licensee files its first New Drug Application (“NDA”) seeking regulatory approval for a Licensed Product in one of the Specified Countries, Licensee shall pay to Licensor a milestone payment of $100,000 in cash. It is understood and agreed
that Licensee shall only be obligated to make one $100,000 payment to Licensor pursuant to this paragraph regardless as to the number of NDAs filed by Licensee for Licensed Product(s) in one or more of the Specified Countries. It is further
understood and agreed that Licensee shall not be obligated to make any payment to Licensor pursuant to this paragraph upon an NDA filing by Licensee in any Country not included in the list of Specified Countries. 

3.2.2. Within ten (10) business days after Licensee receives its first governmental regulatory approval to commercially market and
sell a Licensed Product in one of the Specified Countries, Licensee shall pay to Licensor a milestone payment of $300,000 in cash. It is understood and agreed that Licensee shall only be obligated to make one $300,000 payment to Licensor pursuant to
this paragraph regardless as to the number of governmental approvals obtained by Licensee to commercially market and sell Licensed Product(s) in one or more of the Specified Countries. It is further understood and agreed that Licensee shall not be
obligated to make any payment to Licensor pursuant to this paragraph upon Licensee receiving governmental regulatory approval to commercially market and sell a Licensed Product in any Country not included in the list of Specified Countries.

 4. Royalties. 
 4.1. Percentage Royalty As additional consideration for the exclusive license granted pursuant to Section 2 hereof, Licensee shall pay to Licensor a royalty on a country-by-country basis,
based upon the Net Sales of Licensed Products sold in each country, as follows: 
 4.1.1. Composition of Matter Patent
Claims. For the Net Sales realized by Licensee (or its Affiliates) from a particular country in which there are validly issued patent rights for the Composition of Matter Patent Claims, Licensee shall pay a royalty of four percent (4%) of
said Net Sales, payable for the life of said applicable patent. 
 4.1.2. Method of Use Patent Claims. For the Net Sales
realized by Licensee (or its Affiliates) from a particular country in which there are validly issued patent rights for the Method of Use Patent Claims, but not for Composition of Matter Patent Claims, Licensee shall pay a royalty of three percent
(3%) of said Net Sales, payable for the life of said applicable patent. If both Sections 4.1.1 and 4.1.2 are applicable to the same Net Sales (i.e., validly issued patent rights are for both Composition of Matter Patent Claims and Method of Use
Patent Claims), then Licensee shall pay the four percent (4%) royalty (and not 4% plus 3%). 

  
 4.1.3. Other
Licensed Technology. For the Net Sales realized by Licensee (or its Affiliates) from a particular country in which there are no validly issued patent rights for the Composition of Matter Patent Claims or the Method of Use Claims, Licensee shall
pay a royalty of two percent (2%) of said Net Sales, payable up through the fifth anniversary of the first commercial sale of a Licensed Product in any country. For avoidance of doubt and for an example, if the first such sale occurs in the
year 2000 in one country, then Licensee’s royalty obligation will cease in all countries five years later (in 2005) since there is no patent protection. 
 4.1.4. Competitive Compositions. In the event that the Russian Companies or Licensor develop or acquire a composition or compound which is competitive with the Licensed Product, and the exclusive
rights to said competitive composition or compound have not been granted to Licensee, then the royalty rates specified in Sections 4.1.1, 4.1.2 and 4.1.3 shall be reduced to two percent (2%), one and one-half percent (1.5%) and one percent
(1%) of Net Sales, respectively. 
 4.2. Sublicensee Payments. In the case of Net Sales realized by a sublicensee of
Licensee, instead of Licensee or a sublicensee paying the royalties to Licensor based upon the provisions in Sections 4.1, Licensee shall pay to Licensor an amount equal to twenty-five percent (25%) of the cash actually received by Licensee
from the sublicensee on account of the sublicensee’s Net Sales or on account of the sublicense agreement, including payments made by the sublicensee to Licensee in the nature of running royalties, license fees and milestone payments
(“Included Sublicensee Payments”), but excluding payments made by the sublicensee to Licensee to purchase Licensee’s stock or to fund a specific research and/or development project (“Excluded Sublicensee Payments”).

 4.3. Combination Product. 
 4.3.1. Definition of Combination Product. As used herein, the term “Combination Product” shall mean a Licensed Product which cannot be manufactured, used or sold without
(i) infringing the Licensed Patents, and also (ii) infringing one or more patents held by Licensee or a third party (referred to herein as “other patent rights”). 

4.3.2. Net Sales of Combination Product. The Net Sales of a Combination Product shall be based upon the proportional value of the
contribution of the Licensed Patents, as compared with the aggregate value of all patent rights used for the Combination Product and determined in accordance with the following formula: 

 

									
		 	X = 	 	A 	 	× C	 	
		 	 	B 	 	 	, where

 X = the Net
Sales attributable to the portion of the Combination Product which is attributable to the Licensed Patents, on which Net Sales Licensee shall pay the royalty rate set forth in Section 4.1; and 

  
 A =
the value of the contribution of the Licensed Patents (as compared to the value of the contributions of the other patent rights) used in the Combination Product; and 

B = The aggregate value of all patent rights used for the Combination Product, consisting of both the Licensed Patents
and all other patent rights used in the Combination Product; and 
 C = the Net Sales for the Combination
Product. 
 The values described above shall be determined by the parties hereto in good faith. In the absence of agreement as to said values,
the values shall be determined by arbitration in accordance with the provisions of Section 12.2 hereof. 
 4.4.
Component Product. 
 4.4.1. Definition of Component Product. As used herein, the term “Component
Product” shall mean a Licensed Product which is a distinct component of a larger product which contains multiple components (including, as an example of additional components, proprietary methods sold or licensed with the Component Product).

 4.4.2. Net Sales of Component Product. The Net Sales of a Component Product shall be based upon the proportional value
of the cost to manufacture the Component Product (or the sale price of the Component Product if it is sold separately), as compared with the aggregate value of all components of the aggregate larger product (including methods sold or licensed with
the Component Product and the Component Product) and determined in accordance with the following formula: 
  

									
		 	X = 	 	A 	 	× C	 	
		 	 	B 	 	 	, where

 X = the Net Sales
attributable to the Component Product, on which Licensee is obligated to pay the royalty rate set forth in Section 4.1; and 
 A = the value of the Component Product, based upon cost to manufacture the Component Product, or the sales price of the Component Product if it is sold separately; and 

B = The value of the aggregate larger product, with all components (including methods sold or licensed with the Component
Product, and the Component Product), based upon the same criteria as used for A above; and 
 C = the Net Sales
for the aggregate larger product. 

  
 The values described above shall be
determined by the parties in good faith. In the absence of agreement as to said values, the values shall be determined by arbitration in accordance with the provisions of Section 12.2 hereof. 

4.5. Quarterly Payments. 
 4.5.1. Sales by Licensee. With regard to Net Sales made by Licensee or its Affiliates, royalties shall be payable by Licensee quarterly, within ninety (90) days after the end of each calendar
quarter, based upon Net Sales of Licensed Products during such preceding calendar quarter, commencing with the calendar quarter in which the first commercial sale of any Licensed Product is made. 

4.5.2. Sales by Sublicensees. With regard to cash actually received by Licensee from sublicensees of Licensee or its Affiliates,
based upon Net Sales made by said sublicensees, amounts owed to Licensor shall be payable by Licensee quarterly, within one hundred twenty (120) days after the end of each calendar quarter, based upon Included Sublicensee Payments actually
received by Licensee from sublicensee during such preceding calendar quarter, commencing with the calendar quarter in which Licensee actually receives Included Sublicensee Payments. 

4.6. Duration of Royalty Obligations. The royalty obligations of Licensee as to each Licensed Product shall terminate on a
country-by-country basis as follows: (i) with respect to royalties payable pursuant to Section 4.1.1 or 4.1.2 hereof, termination shall occur concurrently with the expiration of the last to expire of the Composition of Matter Patent Claims
and Method of Use Patent Claims licensed hereunder utilized by or in such Licensed Product in each such country, or (ii) with respect to royalties payable pursuant to Section 4.1.3 hereof, termination shall occur as specified in
Section 4.1.3 herein, if applicable. Notwithstanding any other provision of this Agreement, in the event that, based upon a challenge by a party other than Licensee, its Affiliates or sublicensees, the existing favorable claims of the Licensed
Patents are held to be invalid by the PTO or other applicable foreign governmental authority or any competent court of law, this Agreement shall remain in effect, unless otherwise terminated by Licensee, and Licensee shall thereafter have no further
obligation to pay any royalties hereunder. 
 4.7. Reports. Licensee shall furnish to Licensor at the same time as each
royalty payment is made by Licensee, a written report of Net Sales of Licensed Products (or, in the case of Included Sublicensee Payments, the aggregate amount of such payments) and the royalty due and payable thereon, including a description of any
offsets or credits deducted therefrom, on a product-by-product and country-by-country basis, for the calendar quarter upon which such royalty payment is based. 
 4.8. Records. Licensee shall keep, and cause its Affiliates and sublicensees to keep, complete records and accounts of all sales of Licensed Products in sufficient detail to enable the royalties
payable on Net Sales of each Licensed Product and Included Sublicensee Payments to be determined. Licensor shall have the right to appoint an independent certified public accounting firm approved by Licensee, which approval shall not be unreasonably
withheld, to audit, upon delivery of advance written notice and during normal business hours without interruption of normal business operations, the records of Licensee, its Affiliates and sublicensees as necessary to verify the royalties payable
pursuant to this Agreement. Licensee or its Affiliates shall pay to 

 
Licensor an amount equal to any additional royalties to which Licensor is entitled as disclosed by the audit. Such audit shall be at Licensor’s expense. Licensor may exercise its right of
audit hereunder no more frequently than once in any calendar year. The accounting firm shall disclose to Licensor only such information as is necessary to verify the accuracy of the royalty payments required hereunder, and all such information shall
be treated as Confidential Information by Licensor. Licensee, its Affiliates and sublicensees shall preserve and maintain all records required for audit for a period of three (3) years after the calendar quarter to which the record applies.

 4.9. Foreign Taxes. Any tax required to be withheld by Licensee or its Affiliates under the laws of any foreign
country for the account of Licensor shall be paid by Licensee or its Affiliates for and on behalf of Licensor to the appropriate governmental authority and deducted from any royalties payable by Licensee hereunder. 

5. Sublicense Rights. Licensee shall have the sole and exclusive right to grant sublicenses to any party with respect to the rights conferred upon
Licensee under this Agreement, provided, however, that any such sublicense shall be subject in all respects to all of the provisions contained in this Agreement. Licensee shall pay Licensor, or cause its sublicensees to pay Licensor, amounts owed by
Licensee to Licensor on account of Included Sublicensee Payments as specified in Section 4.2 hereof. 
 6. Obligations Related to
Commercialization. 
 6.1. Commercial Development Obligation. In order to maintain Licensee’s exclusive license
rights granted hereunder in force, Licensee, its Affiliates or sublicensees shall use reasonable efforts to develop the Licensed Technology into a commercially viable Licensed Product, as promptly as is reasonably and commercially feasible, and
thereafter to produce and sell reasonable quantities of the Licensed Product. Licensee shall keep Licensor generally informed as to Licensee’s, its Affiliates’ or sublicensees’ progress in such development, production and sale.

 6.2. Governmental Approvals and Marketing of Licensed Products. Licensee shall have sole authority for, and shall be
responsible for, obtaining all necessary governmental approvals for the development, production, distribution, sale and use of any Licensed Product, at Licensee’s expense. Licensee shall have sole responsibility for any warning labels,
packaging and instructions as to the use of Licensed Products and for the quality control for any Licensed Product. 
 6.3.
Product Liability Indemnity. Licensee hereby agrees to indemnify, defend and hold harmless Licensor from and against any liability or expense arising from any product liability claim asserted by any party as to any Licensed Product made or
sold by Licensee or its Affiliates and sublicensees, other than any claim which arises due to a breach by Licensor, any Russian Inventor or the Russian Companies of any covenant, warranty or representation made to Licensee. 

7. Representations and Warranties. Licensor hereby represents and warrants that (i) he is the rightful and sole owner of exclusive worldwide
rights (except those patents and applications issued or filed in Russia) to the Licensed Technology, (ii) the Licensed Technology is not subject to any lien, license, assignment (other than an assignment to Licensor), security interest or other
encumbrances, (iii) he has made full disclosure to Licensee of all communications with respect to 

 
the Licensed Technology with the PTO and any foreign patent agencies, (iv) he has the power and authority to enter into this Agreement and grant the license provided for hereunder, and
(v) he has no knowledge that the Licensed Technology infringes any patents or other intellectual property rights of third parties, or that any third party is in any way infringing the Licensed Technology covered by this Agreement. 

8. Patent Matters. 

8.1. Patent Prosecution and Maintenance. From and after the date of this Agreement, the provisions of this Section 8.1 shall
control the prosecution and maintenance of the Licensed Patents in the Licensed Territory. Licensee shall direct and control (i) the preparation, filing and prosecution of all domestic and foreign patent applications in the Licensed Territory
relating to Licensed Technology (including any interferences and foreign oppositions); and (ii) the maintenance of any patents issuing therefrom. Licensee shall select the patent attorney, and the fees and expenses incurred by Licensee with
respect to services performed by such patent counsel and any filing or other fees shall be paid by Licensee. Licensor, the Russian Companies and Russian Inventors shall assist Licensee and patent counsel employed or retained by Licensee as necessary
to accomplish the patent processes described hereunder and in the Research Funding Agreement. Licensor, the Russian Inventors and the Russian Companies shall sign all documents which are reasonably necessary to enable Licensee to prosecute and
maintain all patent matters. Licensor shall use diligent efforts to obtain the cooperation and participation of the Russian Companies and the Russian Inventors when reasonably necessary or appropriate for the presentation or maintenance of the
Licensed Products. Licensee shall use good faith and due diligence in determining which foreign countries, in addition to the United States, in which to file for and maintain patent rights, depending on the commercial benefits Licensee can
reasonably anticipate in each country. In as much as Licensee is paying all patent costs, the ultimate decision as to all patent prosecution and maintenance matters shall be made by Licensee. 

8.2. Information to Licensor. Licensee shall keep Licensor informed with regard to the patent applications, re-examination and
maintenance processes. Licensee shall deliver to Licensor copies of all material patent applications, amendments, related correspondence, and other related matters. Licensor shall keep Licensee informed with regard to the Russian patent
applications, re-examinations and maintenance process with respect to the Licensed Technology. Licensor shall deliver to Licensee English translations of copies of all material patent applications, related correspondence, and other related matters
with respect to the Licensed Technology. Licensee shall pay reasonable expenses for translation of such materials, provided, however, that such expenses are pre-approved by Licensee in writing. 

8.3. Patent Costs. The parties hereto agree that the exclusive license granted hereunder is in part in consideration for
Licensee’s payment of past and future patent costs and expenses as described herein. Licensee shall pay for all expenses incurred by Licensee pursuant to Sections 8.1 and 8.2 hereof. Licensee shall not pay for any patent costs paid or incurred
by Licensor or the Russian Inventors or the Russian Companies, other than as specified in Section 3.1 hereof. 
 8.4.
Ownership. The Licensed Patents and the patent applications filed and the patents obtained pursuant to Section 8.1 hereof shall be owned by Licensor, and included in Licensed Technology and the exclusive license granted in this
Agreement. 

  
 8.5. Infringement
Actions. 
 8.5.1. Prosecution and Defense of Infringements. Licensee shall have the right but not the obligation to
prosecute any and all infringements of any Licensed Patent and to defend all charges of infringement arising as a result of the exercise by Licensee, its Affiliates or sublicensees of the rights granted in this Agreement. Licensee may enter into
settlements, stipulated judgments or other arrangements respecting such infringement, at its own expense. Licensor shall permit any action to be brought in his name if required by law, and Licensee shall hold Licensor harmless from any costs,
expenses of liability respecting all such infringements or charges of infringement, except such infringements as shall result from any breach of covenant, warranty or representation made by Licensor herein. Licensor agrees to provide, or use
diligent effort to obtain from the Russian Inventors and Russian Companies, all necessary assistance of a technical nature which Licensee may require in any litigation arising with respect to the Licensed Technology. In the event Licensee elects not
to prosecute any infringement, Licensee shall notify Licensor in writing promptly and Licensor shall have the right to prosecute such infringement on his own behalf. If Licensee elects to prosecute an infringement, then Licensor shall not be
entitled to do so. 
 8.5.2. Allocation of Recovery. Any damages or other recovery from an infringement action undertaken
by Licensee pursuant to Section 8.5.1 shall be retained by Licensee as its exclusive property; but any such recovery, net of Licensee’s costs of litigation, shall be treated as “Net Sales” and Licensee shall pay a royalty thereon
pursuant to Section 4.1 above. If Licensee elects to not prosecute an infringement, and Licensor does prosecute said infringement, then Licensor shall retain any recovery received from said prosecution. 

9. Interests in Intellectual Property Rights. 
 9.1. Preservation of Title. Licensor shall retain full ownership and title to Licensed Technology, and any other patents licensed under this Agreement and shall use his reasonable best efforts to
preserve and maintain such full ownership and title. 
 9.2. Ownership of Improvements and Additional Intellectual
Property. 
 9.2.1. Developed by Licensee. Any improvements to Licensed Technology conceived, developed or reduced to
practice by Licensee, its Affiliates or sublicensees or their employees shall remain the sole and exclusive property of such party, and shall not be included in Licensed Technology under this Agreement. 

9.2.2. License Grant Back. Licensee hereby grants to Licensor an exclusive license in Russia to utilize Licensee’s, its
Affiliates’ or sublicensees’ improvements to Licensed Technology, to use, make, have made, sell or offer to sell all products and/or processes and/or services, with full right to grant sublicenses, subject to Licensor paying to Licensee a
royalty on Net Sales which utilize said improvements, at the same royalty rates as specified in Section 4 hereof. All other terms of this Agreement which are applicable to Licensee shall be applicable to Licensor, as a licensee to use the
improvements in Russia with respect to this section 9.2.2, specifically including items in Sections 4, 5, 6, 8 (in Russia), 11 and 12. 

  
 9.2.3. Developed by
Licensor or the Russian Companies. Any improvements to the Licensed Technology conceived, developed or reduced to practice by Licensor during the term of this Agreement, or by the Russian Companies during the term of the Research Funding
Agreement, shall be included in Licensed Technology and subject to the exclusive license granted hereunder. Examples of such anticipated improvements, include without limitation: (i) novel methods of synthesis, formulation or delivery of Bestim
and related analogs, (ii) therapeutic use applications which cover indications not previously covered in patents, and (iii) new composition of matter claims for Bestim analogs. 
 10. Confidentiality and Publication. 
 10.1. Treatment of Confidential
Information. The parties hereto and the Russian Companies agree that during the term of this Agreement, and for a period of five (5) years after this Agreement terminates, a party receiving Confidential Information of the other party will,
excepting only to the extent needed in connection with the performance of this Agreement or the other agreements referenced herein, (i) maintain in confidence such Confidential Information, (ii) not disclose such Confidential Information to any
third party without prior written consent of the other party and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement. 
 10.2. Publications. In order to protect the rights granted to Licensee hereunder, Licensor and the Russian Companies shall submit to Licensee copies of proposed publications of Licensor or the
Russian Companies which contain subject matter relating to intellectual property licensed hereunder, and shall afford Licensee thirty (30) days to review such proposed publications. Upon timely written request by Licensee, Licensor shall delay
any such publication to facilitate the preparation and filing of a patent application, which delay shall not exceed thirty (30) days from the date Licensee requests such delay. 
 11. Term and Termination. 
 11.1. Term. The term of this Agreement
and the license granted hereunder shall commence on the Effective Date and continue until expiration of the last patent included within the Licensed Patents, unless sooner terminated pursuant to this Section 11. 

11.2. Termination Without Cause. This Agreement may be terminated by Licensee for any reason, at Licensee’s sole discretion,
upon delivery to Licensor of sixty (60) days’ prior written notice of termination. 
 11.3. Termination Upon
Default. Upon the failure of a party to perform any obligation required of it or him to be performed hereunder, and the failure to cure within sixty (60) days after receipt of written notice from the other party specifying in
reasonable detail the nature of such default, the non-defaulting party may deliver to the defaulting party written notice of intent to terminate, such termination to be effective upon the date set forth in such notice. 

Such termination rights shall be in addition to and not in substitution for any other remedies that may be available to the
non-defaulting party. Termination pursuant to this Section 11.3 shall not relieve the defaulting party from liability and damages to the other party for breach of this Agreement. Waiver by either party of a single default or a succession of
defaults shall not deprive such party of any right to terminate this Agreement arising by reason of any subsequent default. 

  
 11.4. Bankruptcy or
Insolvency. The parties agree that the rights and licenses granted under Section 2 of this Agreement, and any intellectual property conceived or reduced to practice during the course of the Research Funding Agreement, are and shall be
deemed to be, for purposes of Section 365 (a) of the U.S. Bankruptcy Code, licenses or rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The parties agree that Licensee, as a
licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The parties further agree that in the event of the bankruptcy or insolvency of Licensee, this Agreement
and the rights granted to Licensee hereunder may be transferred by Licensee or any trustee appointed for the estate of Licensee, provided such transferee shall agree in writing to comply with all of the terms and conditions set forth herein and to
cure any financial defaults by Licensee. In the event of the bankruptcy or insolvency of Licensee or Licensor, this Agreement shall remain in full force and effect. 
 11.5. Rights Upon Expiration. Neither party shall have any further rights or obligations upon the regularly scheduled expiration of this Agreement other than the obligation of Licensee to make any
and all reports and payments for the final quarter period. Provided, however, that upon such expiration, each party shall be required to continue to abide by its confidentiality obligations as described in Section 10, and Licensee shall
continue to abide by its obligation to indemnify Licensor as described in Section 6.3 for products sold prior to the termination. 
 11.6. Rights Upon Termination. Notwithstanding any other provision of this Agreement, upon any termination of this Agreement prior to the regularly scheduled expiration date of this Agreement, the
license granted hereunder shall terminate. Except as otherwise provided in Section 11.7 of this Agreement with respect to work-in-progress, upon such termination, Licensee shall have no further right to develop, manufacture or sell any Licensed
Products, or to otherwise use any Licensed Technology. Any such termination shall not relieve either party from any obligations accrued to the date of such termination. Upon such termination, each party shall be required to abide by its
nondisclosure obligations as described in Section 10.1, and, provided termination was not initiated by Licensee due to Licensor’s breach hereunder, Licensee shall continue to abide by its obligations to indemnify Licensor as described in
Section 6.3 for products sold prior to the termination. 
 11.7. Work-in-Progress. Upon any early termination of
this Agreement and the license granted hereunder, Licensee shall be entitled to finish any work-in-progress and to sell any completed inventory of Licensed Products which remain on hand as of the date of termination, so long as Licensee pays to
Licensor the royalties applicable to such sales in accordance with the terms and conditions as set forth in this Agreement. 
 12. General
Provisions. 
 12.1. Independent Contractors. The relationship between Licensor and Licensee is that of independent
contractors. Licensor and Licensee are not joint venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent contracting parties. Licensor and Licensee shall have no power
to bind or obligate each other in any manner, other than as is expressly set forth in this Agreement. 

  
 12.2.
Arbitration. Any matter or disagreement arising under this Agreement shall be submitted for decision to a panel of three neutral arbitrators with expertise in the subject matter to be arbitrated. One arbitrator shall be selected by each party
and the two arbitrators so selected shall select the third arbitrator. The arbitration shall be conducted in accordance with the Rules of the American Arbitration Association. The decision and award rendered by the arbitrators shall be final and
binding. Judgment upon the award may be entered in any court having jurisdiction thereof. Any arbitration shall be held in Santa Clara County, California, or such other place as may be mutually agreed upon in writing by the parties. 

12.3. Entire Agreement; Modification. This Agreement sets forth the entire agreement and understanding between the parties as to
the subject matter hereof. There shall be no amendments or modifications to this Agreement, except by a written document which is signed by both parties. The parties acknowledge that they are also parties to related agreements entitled (i) Research
Funding Agreement, (ii) Russian Companies’ Acknowledgment, and (iii) Consulting Agreement. 
 12.4.
Headings. The headings of the several sections are inserted for convenience of reference and are not intended to be a part of or affect the meaning or interpretation of this Agreement. 

12.5. Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of California,
without regard to conflict of laws rules. 
 12.6. Severability. If any one or more of the provisions of this Agreement
is held to be invalid or unenforceable by a court of competent jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions thereof. The parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable provision such that the objectives contemplated by them when entering this Agreement may be realized. 
 12.7. No Waiver. Any delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such party’s rights
to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 

12.8. Notices. Any notices required by this Agreement shall be in writing, shall refer to this Agreement and shall be sent by
registered or certified mail, postage prepaid, or by facsimile, telex or cable, charges prepaid, or by overnight courier, charges prepaid to the addresses set forth below unless subsequently changed by written notice to the other party: 

 

			
	For Licensee:	  	 SciClone Pharmaceuticals, Inc.
 901 Mariner’s Island Blvd.
 San Mateo, CA 94404

Attention: Alfred Rudolf, M.D.
 Fax No.: (415)
358-3469

		
	For Licensor:	  	 Edward T. Wei
 480 Grizzly
Peak Blvd.
 Berkeley, CA 94708
 Fax
No.: 510-524-9040

  
 Notice shall be deemed delivered upon
the earlier of (i) when received, (ii) three (3) days after deposit into the mail, or (iii) the date notice is sent via facsimile, telex or cable, (iv) the day immediately following delivery to overnight courier (except
Sunday and holidays). 
 12.9. Binding Upon Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of any successors in interest and assigns of Licensor and Licensee. Neither this Agreement nor any interest hereunder is assignable in part or in whole without the prior written consent of the other, which consent shall not be unreasonably
withheld; provided, however, that Licensee may assign this Agreement without Licensor’s consent (i) to any of its Affiliates, or (ii) to any successor to Licensee by merger or consideration, or to the acquiror of all or
substantially all of the business unit to which this Agreement relates, in each case, any such successor or assignee shall expressly assume in writing the performance of all the terms and conditions of this Agreement to be performed by the assigning
party. 
 12.10. Interpretation of Agreement. Each of the parties hereto has reviewed the terms of this Agreement with
such party’s counsel. Therefore, notwithstanding Section 1654 of the California Civil Code, the terms of the Agreement shall not be interpreted against either party in the event of any uncertainty with regard to the language in this
Agreement. 
 12.11. Counterparts This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original but all of which shall constitute one and the same Agreement. Signatures may be transmitted by facsimile. 

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives as of the date set forth above.

  

							
	LICENSOR:	 		 	LICENSEE:
			
		 		 	SCICLONE PHARMACEUTICALS, INC.
				
	 /s/ Edward T. Wei, Ph.D.
	 		 	By:	 	 /s/ D.R. Sellers

	Edward T. Wei, Ph.D.	 		 	
			
		 		 	SCICLONE PHARMACEUTICALS INTERNATIONAL LTD.
				
		 		 	By:	 	 /s/ Mark A. Culhane

  
 EXHIBIT A

 Licensed Technology and Licensed Patents 

 

	1.	All the inventions, patent applications, patent rights, know-how and technology which are described in the following pending patent applications:

 U.S. Application Serial No. 08/634,718, filed April 18, 1996 

PCT Application No. PCT/US 96/17913, filed November 13, 1996 
 The Inventors are: 
 Alexander A. Kolobov 

Andrey S. Simbirtsev 
 Sergey V. Kulikov 
 Alexey N. Prusakov 

Natalia M. Kalinina 
 Natalia V. Pigareva 
 Alexander U. Kotov 

Vladimir M. Shpen 
 Oleg A. Kaurov 
 Sergey A Ketlinsky 

 

	2.	All patents issued based on divisionals, continuations, continuations-in-part, reissues, re-examinations and extensions of the patent rights described in paragraph 1
above, together with all corresponding foreign patents, except for those issued in Russia, and together with all related pending patent applications and inventor’s certificates, and together with all patents and patent applications covering
improvements to the inventions described in the foregoing, filed or issued in any country except in Russia. 

  

	3.	All future patent applications and patents filed and issued in individual countries as a result of “going national” under the PCT Application identified in
paragraph 1 above.Separation Agreement - Hilary Schneider

  
 Exhibit 10.19

 [Yahoo! Letterhead] 
 October 1, 2010 
 Hilary Schneider 
 Dear Hilary: 
 As we discussed, Yahoo! Inc. (“Yahoo!” or the
“Company”) is prepared to offer you transition benefits to aid in your employment transition. Subject to the approval of the Compensation Committee of the Board of Directors of Yahoo! (“Compensation Committee”), if you
(1) sign and comply with the terms of this separation agreement (the “Agreement”), which contains a release of claims, and (2) return your signed Agreement to Yahoo! Human Resources by the deadline specified in this
Agreement (collectively these are the “Agreement Eligibility Requirements”), then Yahoo! will continue to employ you through the Separation Date specified below (unless you resign prior to that date) and will pay you a payment as
described below in paragraph 3. Subject to the approval of the Compensation Committee, if you (1) continue to comply with the terms specified in this Agreement, (2) do not resign prior to April 29, 2011, (3) sign the Supplemental
Release (which contains a release of claims and is attached as Exhibit A) on or after the Separation Date, (4) return your signed Supplemental Release to Yahoo! Human Resources by the deadline specified in the Supplemental Release,
(5) comply with the terms of the Supplemental Release, and (6) do not revoke the Supplemental Release during the applicable revocation period (collectively these are the “Supplemental Release Eligibility Requirements”),
then you will receive the Transition Bonus (described below) as specified in the Agreement following the Separation Date. 
 If you do not
comply with the Agreement Eligibility Requirements, your employment may terminate prior to the Separation Date described below, and the Company will not pay some of the payments and benefits specified in this Agreement. If you do not comply with the
Supplemental Release Eligibility Requirements, you will not receive the Transition Bonus and some of the other benefits specified in this Agreement. 
 1. Separation. If you meet the Agreement Eligibility Requirements and do not resign prior to April 29, 2011, then your last day of employment with the Company and your employment termination
date will be the earlier of (a) April 29, 2011, (b) the date on which the Company terminates your employment due to your failure to comply with material Company 

  Page
 2
 
  

 
policies and procedures, or (c) the date of your death (as applicable, the “Separation Date”). You will be expected to continue to perform your current job duties relating
to the Americas region and assist with the transition of work through December 31, 2010. Thereafter, you will work on special projects as assigned by Yahoo! and be available on an “on call” basis through your Separation Date to
respond to questions and support any transition as requested by Yahoo!. Although you will be expected to perform assigned job duties and projects through your Separation Date, Yahoo! may allocate some or all of your job responsibilities to others.
You hereby resign as an Executive Vice President of the Americas region of Yahoo! (and as an officer and director of the Company and any subsidiary, as well as a fiduciary of any benefit plan of the Company) as of December 31, 2010 or sooner if
requested by Yahoo!, but such resignation shall not constitute a resignation of your employment. You shall execute such additional documents as reasonably requested by the Company to evidence your resignation (including documents that evidence the
resignation of your officer position). The Company will allow you reasonable time off in order to conduct a job search or attend to personal matters, provided that you obtain the advance approval of your manager for such absences. From the date of
this Agreement to your Separation Date (“Transition Period”), if you meet the Agreement Eligibility Requirements, Yahoo! will continue to pay you your regular base salary, and you will continue to be eligible for benefits under the
Company’s plans, however, you shall not be eligible for any new equity grants or other new incentive or bonus opportunities. 
 2. Accrued Salary and Paid Time Off. On the Separation Date, Yahoo! will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to payroll
deductions and required withholdings. You are entitled to any earned payments regardless of whether or not you sign this Agreement or the Supplemental Release. 

3. Executive Incentive Plan Bonus. Subject to the approval of the Compensation Committee, if your Separation
Date is on or after March 15, 2011 and you meet the Agreement Eligibility Requirements, then your 2010 Executive Incentive Plan (EIP) incentive bonus payout will be paid at a minimum of the 2010 EIP Bonus Pool funded level.1 If you meet the eligibility requirements specified in this paragraph,
your 2010 EIP incentive bonus payout will be paid in 2011 on the same schedule as it is paid to other employees of Yahoo!. This bonus is subject to payroll deductions and required withholdings. 

Subject to the approval of the Compensation Committee, if your Separation Date is before March 15, 2011 and you meet the
Supplemental Release Eligibility Requirements, then as part of this Agreement, Yahoo! will pay you a payment in lieu of your 2010 Executive Incentive Plan (EIP) incentive bonus payout, subject to payroll deductions and required withholding. The
payment will be calculated by multiplying your EIP target incentive by the 2010 EIP Bonus Pool funded level.2 If you meet the eligibility requirements specified in this paragraph, the payment will be paid to you in 2011 at the time that Yahoo! pays its employees their EIP incentive bonus payout. 

 
  

	1	 For example, if the 2010 EIP Bonus Pool is funded at 50%, then your 2010 EIP incentive bonus payout will be equal to your EIP target incentive
multiplied by 50%. Yahoo!, in its sole discretion, may increase your 2010 EIP incentive bonus payout based on its assessment of your performance. 

	2	 For example, if the 2010 EIP Bonus Pool is funded at 50%, then your payment will be equal to your EIP target incentive multiplied by 50%. Yahoo!, in
its sole discretion, may increase your payment. 

  Page
 3
 
  

 For the sake of clarity, subject to the approval of the Compensation Committee, you will be entitled to
either (but not both) the 2010 EIP incentive bonus or the payment in lieu of your 2010 EIP incentive bonus (both as described above), provided you meet the Agreement Eligibility Requirements or the Supplemental Release Eligibility Requirements, as
applicable. 
 You will not be eligible for any 2011 EIP incentive bonus payout. 

4. Transition Benefits. Subject to the approval of the Compensation Committee, if you comply with the
Supplemental Release Eligibility Requirements, then as part of this Agreement, Yahoo! will pay you a transition bonus of four hundred twenty thousand dollars ($420,000.00) (“Transition Bonus”), subject to payroll deductions and
required withholdings.3 The Transition Bonus will be paid
in a lump sum within twenty (20) business days after the Effective Date (as described in the Supplemental Release), but not earlier than January 1, 2011 or later than December 31, 2011, provided that you meet the Supplemental Release
Eligibility Requirements. Should you accept an offer of employment for another position at Yahoo! prior to the payment of the Transition Bonus described in this Agreement, your at-will employment at Yahoo! will continue and you will not be eligible
for the Transition Bonus or other benefits described in this Agreement. 
 5. Health Insurance. Your group health
insurance will cease on the last day of the month of your Separation Date. At that time, you will be eligible to continue your group health insurance benefits at your own expense under the terms and conditions of the applicable benefit plan,
federal COBRA law and/or, if applicable, state insurance laws. For more information on continued group health coverage, please contact Yahoo! Benefits at (888) 862-5822.  

6. Obligations. Except as provided in Paragraph 1 above, prior to your Separation Date, you shall devote your full business
efforts and time to Yahoo! (other than taking reasonable time off in order to conduct a job search). You agree that you will not engage in any activities that are in violation of Yahoo!’s Code of Ethics or any other Yahoo! policy. 

 
  

	3	 If you do not comply with the Supplemental Release Eligibility Requirements or you engage in misconduct, you will not receive the Transition Bonus and
some of the other benefits specified in this Agreement and the Supplemental Release. For purposes of this Agreement, “misconduct” shall include the following: (1) your failure or refusal to comply in any material respect with lawful
Company policies or lawful directives, (2) your material breach of any contract or agreement between you and the Company (including but not limited to this Agreement, the Supplemental Release, and the Employee Confidentiality and Assignment of
Inventions Agreement between you and Yahoo!), or your material breach of any statutory duty, fiduciary duty or any other material obligations that you owe to the Company, or (3) your commission of an act of fraud, theft, embezzlement or other
unlawful act against the Company or involving its property or assets or your engaging in unprofessional, unethical or other intentional acts that materially discredit the Company or are materially detrimental to the reputation, character or standing
of the Company. 

  Page
 4
 
  

  
 7. Tax Matters.

 (a) Withholding. Yahoo! will withhold required federal, state and local taxes from any and all payments
contemplated by this Agreement. 
 (b) Responsibility for Taxes. Other than Yahoo!’s obligation and right to
withhold federal, state and local taxes, you will be responsible for any and all taxes, interest, and penalties that may be imposed with respect to the payments contemplated by this Agreement (including, but not limited to, those imposed under
Internal Revenue Code Section 409A). To the extent that this Agreement is subject to Internal Revenue Code Section 409A, you and Yahoo! agree that the terms and conditions of this Agreement shall be construed and interpreted to the maximum
extent reasonably possible, without altering the fundamental intent of this Agreement, to comply with and avoid the imputation of any tax, penalty or interest under Code Section 409A. 

8. Stock Options. If you have been granted options to purchase shares of Yahoo!’s common stock, your options will cease to
vest on the Separation Date, and any options that are unvested as of the Separation Date shall terminate and be forfeited as of the Separation Date. Your rights to exercise your options that are vested as of the Separation Date are set forth in the
applicable stock plan and your corresponding notice of stock option grant and stock option agreement. Nothing in this Agreement modifies the terms applicable to your stock options. For more information about your stock options (if any), please
review your stock option information via your E*TRADE online access at www.etrade.com. The E*TRADE website provides a complete listing of your stock option grant details, including the expiration date of your options. Should you have any
questions, please contact E*TRADE directly at 800-838-0908 or Yahoo! Stock Plan Services at [private]@yahoo-inc.com. 
 9. Restricted Stock and Restricted Stock Units. If you have been granted restricted stock and/or restricted stock units under Yahoo!’s 1995 Stock Plan, as amended, or other applicable stock
plan, your restricted stock and restricted stock units will cease to vest on the Separation Date, and all restricted stock and restricted stock units that are unvested as of the Separation Date shall terminate and be forfeited as of the Separation
Date. Nothing in this Agreement modifies the terms applicable to your restricted stock or restricted stock units. For more information about your restricted stock and restricted stock units (if any), please review your information via your E*TRADE
online access at www.etrade.com. Should you have any questions, please contact E*TRADE directly at 800-838-0908 or Yahoo! Stock Plan Services at [private]@yahoo-inc.com. 

10. Employee Stock Purchase Plan. Contributions to your Employee Stock Purchase Plan (“ESPP”) will cease as of
the Separation Date. Under the terms of the ESPP, all contributions you made to the ESPP that have not been used to purchase stock will be returned to you without interest by Yahoo! Payroll. For more information about the ESPP, please review your
information via your E*TRADE online access at www.etrade.com. Should you have any questions, please contact E*TRADE directly at 800-838-0908 or Yahoo! Stock Plan Services at [private]@yahoo-inc.com.

  Page
 5
 
  

  
 11.
401(k) Plan. If you have questions about your 401(k) account, please contact Yahoo! Benefits at (888) 862-5822. 

12. Life Insurance. Your life insurance coverage will cease on or before the Separation Date under the terms of the life insurance
plan. The Company will provide you with information about the option to convert this coverage to an individual policy. 
 13.
Flexible Spending Plan. If you enrolled in the Company’s Flexible Spending Plan and established a Healthcare Reimbursement Account and/or Dependent Care Reimbursement Account for the 2010 Plan Year, you have 90 days (as long as it is prior
to March 31, 2011) following your Separation Date to submit any covered expenses for reimbursement provided the expenses were incurred from January 1, 2010 through the earlier of your Separation Date or December 31, 2010. If you
enrolled in the Company’s Flexible Spending Plan and established a Healthcare Reimbursement Account and/or Dependent Care Reimbursement Account for the 2011 Plan Year, you have 90 days (as long as it is prior to March 31, 2012) following
your Separation Date to submit any covered expenses for reimbursement provided the expenses were incurred from January 1, 2011 through your Separation Date. You may only submit expenses that you incurred prior to the Separation Date.

 14. Other Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement, you will not
receive any additional compensation, incentive payments, severance, transition benefits, or other benefits after the Separation Date, with the exception of any benefit, the right to which has vested, under the express terms of a written benefit plan
of the Company. 
 15. Expense Reimbursements. You agree that, within thirty (30) days following your Separation
Date, you will submit your final expense reimbursement statement and required documentation reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. Yahoo! will reimburse you for expenses
pursuant to its regular business practice. You may only submit expenses that you incurred prior to the Separation Date. For a copy of the Yahoo! expense form, please email [private]@yahoo-inc.com. You should submit completed expense reports
and receipts to the Expense Report Department at Yahoo!, 701 First Avenue, Sunnyvale, California 94089.  
 16.
Invention and Assignment to Yahoo!. During the Transition Period and after your Separation Date, you agree to perform promptly, all acts deemed necessary or desirable by Yahoo! to permit and assist it, at its expense, in obtaining and enforcing
the full benefits, enjoyment, rights and title throughout the world in all intellectual property assigned to Yahoo! pursuant to your Employee Confidentiality and Assignment of Inventions Agreement(s) or similar agreement(s) including, but not
limited to, disclosing information, executing documents and assisting or cooperating in legal proceedings. You understand and agree that you will not be eligible to receive the severance and other benefits specified in this Agreement until you
have performed the acts specified in this paragraph (if requested by Yahoo!), such performance to be deemed complete at Yahoo!’s sole discretion.

  Page
 6
 
  

  
 17. Return of
Company Property. By your Separation Date or earlier if requested by Yahoo!, you agree to return to Yahoo! all hard copy and electronic documents (and all copies thereof) and other property belonging to Yahoo!, its subsidiaries and/or affiliates
that you have had in your possession at any time, including, but not limited to, files, notes, notebooks, correspondence, memoranda, agreements, drawings, records, business plans, forecasts, financial information, specifications, computer-recorded
information, tangible property (including, but not limited to, computers, code, software, technical products, product requirements, user interface documentation, PDAs, pagers, telephones, credit cards, entry cards, identification badges and keys),
and any materials of any kind that contain or embody any proprietary or confidential information of the Company, its subsidiaries or affiliates (and all reproductions thereof in whole or in part). If you discover after your Separation Date that you
have retained any proprietary or confidential information (including, but not limited to, proprietary or confidential information contained in any electronic documents or e-mail systems in your possession or control), you also agree immediately upon
discovery to send an email to [private]@yahoo-inc.com and inform Yahoo! of the nature and location of the proprietary or confidential information that you have retained so that Yahoo! may arrange to remove, recover, and/or collect such
information. The Transition Bonus and other benefits under this Agreement will not be paid or provided until all Company property has been returned to Yahoo!. 
 18. Proprietary Information Obligations. You acknowledge your continuing obligations under your Employee Confidentiality and Assignment of Inventions Agreement(s) or similar agreement(s)
(collectively “NDA”), including your obligation not to use or disclose any confidential or proprietary information of the Company, its subsidiaries or affiliated entities and not to solicit Yahoo! employees and, to the extent
permitted by applicable law, not to solicit Yahoo! customers as specified in your NDA. 
 19. Confidentiality. You agree
to hold the provisions of this Agreement and the Supplemental Release in strictest confidence and you agree not to publicize or disclose their terms in any manner whatsoever until Yahoo! publicly files the Agreement and/or Supplemental Release;
provided, however, that you may discuss this matter in confidence with your immediate family and your attorney or other professional advisor, so long as those parties agree to be bound by this confidentiality agreement. Nothing in this
section prohibits you from disclosing the terms of this Agreement in order to enforce the Agreement or as otherwise required or permitted by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement or the
Supplemental Release to any current or former Yahoo! employee until Yahoo! publicly files the Agreement and/or Supplemental Release. You acknowledge that Yahoo! has certain public filing obligations with which it must comply relating to this
Agreement and/or Supplemental Release. 
 20. Nondisparagement. You agree not to make negative comments or otherwise
disparage Yahoo! or its officers, directors, employees, shareholders or agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided however that statements which are complete and
made in good faith in response to any question, inquiry or request for information required by legal process shall not violate this paragraph. 

  Page
 7
 
  

  
 21. Release of
Claims. In consideration for, and as a condition of the benefits and other consideration under this Agreement, to which you are not otherwise entitled, you hereby generally and completely release the Company and its directors, officers,
employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively “Released Party”) from any and all claims, liabilities and obligations,
both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement. This general release includes, but is not limited to:
(1) all claims arising out of or in any way related to your employment with the Company or the termination of that employment; (2) all claims related to your compensation or benefits from the Company, including wages, salary, variable
compensation, incentive payments, bonuses, commissions, vacation pay, expense reimbursements (to the extent permitted by applicable law), severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company;
(3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including without limitation claims for fraud, defamation, emotional distress, and
discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including without limitation claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal
Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Worker Adjustment and Retraining Notification Act (as amended) and similar laws in other jurisdictions, the Employee Retirement Income Security
Act of 1974 (as amended), the Family and Medical Leave Act of 1993, and the California Fair Employment and Housing Act (as amended) and similar laws in other jurisdictions, but not including claims under the federal Age Discrimination in Employment
Act of 1967, as amended. To the maximum extent permitted by law, you also promise never directly or indirectly to bring or participate in an action against any Released Party under California Business & Professions Code Section 17200
or under any other unfair competition law of any jurisdiction. If, notwithstanding the above, you are awarded any money or other relief under such a claim, you hereby assign the money or other relief to the Company. Your waiver and release specified
in this paragraph do not apply to any rights or claims that may arise after the date you sign this Agreement. 
 This Agreement includes a
release of claims of discrimination and retaliation on the basis of workers’ compensation status, but does not include claims for workers’ compensation benefits. Excluded from this Agreement are any claims which by law cannot be
waived in a private agreement between employer and employee including, but not limited to, the right to file a charge with or participate in an investigation conducted by the Equal Employment Opportunity Commission (“EEOC”) or any
state or local fair employment practices agency. You waive, however, any right to any monetary recovery or other relief should the EEOC or any other agency pursue a claim on your behalf. Finally, the release included in this Agreement does not
constitute a release of any rights to indemnification you have under any agreement between you and the Company on the date hereof, any Company insurance policy relating to such matters under which you are covered, the Company’s charter
documents and/or applicable law. 
 22. Representations. You acknowledge and represent that you have not suffered any
discrimination, harassment, retaliation, or wrongful treatment by any Released Party. You also acknowledge and represent that you have not been denied any rights including, but not limited 

  Page
 8
 
  

 
to, rights to a leave or reinstatement from a leave under the Family and Medical Leave Act of 1993, the Uniformed Services Employment and Reemployment Rights Act of 1994, or any similar law of
any jurisdiction. 
 23. Release of Unknown Claims. You acknowledge that you have read and understand Section 1542
of the California Civil Code: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially
affected his or her settlement with the debtor.” You hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to your release of any unknown or
unsuspected claims. 
 24. Cooperation. You agree to reasonably cooperate with and make yourself available on a
continuing basis to Yahoo! and its representatives and legal advisors in connection with any matters in which you are or were involved or any existing or future claims, investigations, administrative proceedings, lawsuits and other legal and
business matters, as reasonably requested by Yahoo!. You also agree that within two (2) business days of receipt (or more promptly if reasonably required by the circumstances) you shall send the Company copies of all correspondence (for
example, but not limited to, subpoenas) received by you in connection with any legal proceedings involving or relating to Yahoo!, unless you are expressly prohibited by law from doing so. You agree that you will not voluntarily cooperate with any
third party in any actual or threatened claim, charge, or cause of action of any nature whatsoever against any Released Party. You understand that nothing in this Agreement prevents you from cooperating with any government investigation. 

25. Miscellaneous. This Agreement, including its Exhibit, constitutes the complete, final and exclusive embodiment of the entire
agreement between you and the Company with regard to this subject matter. Without limiting the generality of the preceding sentence, this Agreement, including its Exhibit, specifically supersedes any rights that you may have otherwise had (or may
have otherwise become entitled to) under each of (1) your August 2006 employment letter agreement with the Company, (2) your November 20, 2008 letter regarding payments and equity vesting, and (3) the Company’s Change in
Control Severance Plans. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This
Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of Yahoo!. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to
the benefit of both you and the Company, their heirs, successors and assigns. Any successor to the Company’s business shall expressly assume the Company’s obligations under this Agreement. If any provision of this Agreement is determined
to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable. This Agreement will be deemed
to have been entered into and will be construed and enforced in accordance with the laws of the state of California. 

  Page
 9
 
  

 IF THIS AGREEMENT IS
ACCEPTABLE TO YOU, PLEASE SIGN BELOW AND RETURN THE ORIGINAL TO DAVID
WINDLEY AT YAHOO!, 701 FIRST AVENUE, SUNNYVALE, CALIFORNIA 94089 BY 5:00 P.M. ON
OCTOBER 5, 2010. 
 I wish you good luck in your future endeavors. 

Sincerely, 
 YAHOO!
INC. 
  

			
	By:	 	 /s/ David Windley

		 	David Windley
		 	Chief Human Resources Officer
	
	Exhibit A – Supplemental Release
	
	AGREED AND VOLUNTARILY EXECUTED:
	
	 /s/ Hilary Schneider

	Hilary Schneider
	
	 10/1/10

	Date
	
	cc: Personnel File

  
 Exhibit A 

Page 1 
 SUPPLEMENTAL RELEASE

 (To be signed on or after the Separation Date) 
 In return for payment of the Transition Bonus and other benefits as described in my separation agreement, dated October 1, 2010 (“Agreement”), the terms of which are incorporated
herein by reference, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns
(collectively “Released Party”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to and on the date I
sign this Supplemental Release. This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my
compensation or benefits from the Company, including wages, salary, bonuses, commissions, vacation pay, expense reimbursements (to the extent permitted by applicable law), severance pay, fringe benefits, stock, stock options, or any other ownership
interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including without limitation claims for fraud, defamation,
emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including without limitation claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims
arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the federal Worker Adjustment and
Retraining Notification Act (as amended) and similar laws in other jurisdictions, the Employee Retirement Income Security Act of 1974 (as amended), the Family and Medical Leave Act of 1993, and the California Fair Employment and Housing Act (as
amended) and similar laws in other jurisdictions. To the maximum extent permitted by law, I also promise never directly or indirectly to bring or participate in an action against any Released Party under California Business & Professions
Code Section 17200 or under any other unfair competition law of any jurisdiction. If, notwithstanding the above, I am awarded any money or other relief under such a claim, I hereby assign the money or other relief to the Company. I understand
that the waiver and release specified in this paragraph do not apply to any rights or claims that may arise after the date I sign this Supplemental Release. 
 This Supplemental Release includes a release of claims of discrimination and retaliation on the basis of workers’ compensation status, but does not include workers’ compensation
claims. Excluded from this Supplemental Release are any claims which by law cannot be waived in a private agreement between employer and employee, including but not limited to the right to file a charge with or participate in an investigation
conducted by the Equal Employment Opportunity Commission (“EEOC”) or any state or local fair employment practices agency. I waive, however, any right to any monetary recovery or other relief should the EEOC or any other agency
pursue a claim on my behalf. Finally, the release included in this Supplemental Release does not constitute a release of any rights to indemnification I have under any agreement between the Company and me in effect on the date hereof, any Company
insurance policy relating to such matters under which I am covered, the Company’s charter documents and/or applicable law. 

 Exhibit A 
 Page 2 
  

 I acknowledge and represent that I have not suffered any age or other discrimination,
harassment, retaliation, or wrongful treatment by any Released Party. I also acknowledge and represent that I have not been denied any rights including, but not limited to, rights to a leave or reinstatement from a leave under the Family and Medical
Leave Act of 1993, the Uniformed Services Employment and Reemployment Rights Act of 1994, or any similar law of any jurisdiction. 
 I acknowledge and agree that I have been paid all wages due and that, as to any further alleged wages, I agree that there is a good-faith dispute as to whether such wages are due, and based on this
good-faith dispute, I release and waive any and all further claims regarding any alleged unpaid wages and any corresponding penalties, interest, or attorneys’ fees, in exchange for the consideration provided in this Supplemental Release.

 I agree that I am voluntarily executing this Supplemental Release. I acknowledge that I am knowingly and voluntarily
waiving and releasing any rights I may have under the ADEA and that the consideration given for the waiver and release is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this
writing, as required by the ADEA, that: (a) my waiver and release specified in this paragraph do not apply to any rights or claims that may arise after the date I sign this Supplemental Release; (b) I have been advised to consult with an
attorney prior to signing this Supplemental Release; (c) I have at least twenty-one (21) days from the date that I receive this Supplemental Release to consider this Supplemental Release (although I may choose to sign it any time on or
after my Separation Date); (d) I have seven (7) days after I sign this Supplemental Release to revoke it (“Revocation Period”); and (e) this Supplemental Release will not be effective until I have returned it to
Yahoo!’s Human Resources Department and the Revocation Period has expired (the “Effective Date”).  

I UNDERSTAND THAT THIS SUPPLEMENTAL RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. In giving this release, which includes
claims which may be unknown to me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code, which states: “A general release does not extend to claims which the creditor does not know or
suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to my release of any unknown or unsuspected claims I may have against the Released Party. 
 Yahoo! will withhold required federal, state and local taxes from any and all payments contemplated by the Agreement and this Supplemental Release. Other than Yahoo!’s obligation and right to
withhold federal, state and local taxes, I will be responsible for any and all taxes, interest, and penalties that may be imposed with respect to the payments contemplated by the Agreement and this Supplemental Release (including, but not limited
to, those imposed under Internal Revenue Code Section 409A). To the extent that the Agreement and/or this Supplemental Release is subject to Code Section 409A, Yahoo! and I agree that the terms and conditions of the Agreement and this
Supplemental Release shall be construed and interpreted to the maximum extent reasonably possible, without altering their fundamental intent, to comply 

 Exhibit A 
 Page 3 
  

 
with and avoid the imputation of any tax, penalty or interest under Code Section 409A. 
 Certification Regarding Search and Return of Yahoo! Property. I hereby certify that: (1) prior to the date that I signed this Supplemental Release, I conducted a good faith and diligent
search for any Yahoo! business data, whether or not such data would be considered confidential or proprietary and/or whether such data constitutes a legally protectable trade secret, including hard copy and all electronically stored data
(“Yahoo! Business Data”) that may be in my possession. This search included reviewing the contents of any personal email accounts and Instant Messenger archives that I maintain, home computers, and other electronic computer media
(CDs, USB thumb drives, disks, back-up drives, etc.) which I may have used during my employment to send, receive or store Yahoo! Business Data (“Personal Computer Media”); (2) to the extent I located any Yahoo! Business Data
pursuant to my search described above, I have returned all originals and copies of such data to Yahoo!, and made arrangements for Yahoo!, at its option, to retrieve, destroy and/or permanently delete such data from my Personal Computer Media such
that I cannot recover the data or access it in any manner; (3) I have not copied, saved, downloaded, retained, disclosed, photographed, or transmitted in any form whatsoever, any Yahoo! Business Data to any source except in the course of
performing my duties for Yahoo! and for Yahoo!’s benefit; (4) I have not copied, saved, downloaded, retained, disclosed, photographed, or transmitted in any form whatsoever, any Yahoo! Business Data to any source for the purpose of
retaining such data after my Separation Date or taking such data with me to my next employer or using it in connection with any subsequent employment; (5) as of the date that I sign this Supplemental Release, it is my good faith belief that I
do not possess any Yahoo! Business Data in tangible or electronic form, except employment-related documents such as wage, benefit, and related information specific to the terms and conditions of my employment with Yahoo!; (6) to the extent I
had any question about whether a Yahoo! document contains Yahoo! Business Data, I have inquired of Yahoo! in writing at [private]@yahoo-inc.com concerning the specific document and received clarification as to whether such document relates
solely to my employment as defined in this paragraph or whether Yahoo! required me to return the document(s) (in which case, I certify that such document(s) have been returned); (7) I have returned all keys, access cards, credit cards,
identification cards, phones, computers and related company-issued devices, including electronic mail devices, PDAs and/or electronic organizers, and other property and equipment belonging to Yahoo! (“Company Property”);
(8) within the six (6) month period prior to my Separation Date, I have not intentionally or knowingly deleted Yahoo! Business Data, except in the normal course of performing my duties and responsibilities for Yahoo!; (9) other than
in the normal course of performing my duties and/or responsibilities for Yahoo! and for Yahoo!’s benefit, I did not copy, back-up, or download Yahoo! Business Data that was contained on Company Property other than back-ups created on Yahoo!
computer systems, media or other property accessible only by Yahoo! and for Yahoo!’s benefit; and (10) other than in the normal course of performing my duties and/or responsibilities for Yahoo! and for Yahoo!’s benefit, I did not
delete or wipe or attempt to delete or wipe Yahoo! Business Data that was contained on Company Property. 
 The Agreement and
this Supplemental Release constitute the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to this subject matter. Without limiting the generality of the preceding sentence, the Agreement and
this Supplemental Release specifically supersede any rights that I may have otherwise had (or 

 Exhibit A 
 Page 4 
  

 
may have otherwise become entitled to) under each of (1) my August 2006 employment letter agreement with the Company, (2) my November 20, 2008 letter regarding payments and equity
vesting, and (3) the Company’s Change in Control Severance Plans. The Agreement and this Supplemental Release are entered into without reliance on any promise or representation, written or oral, other than those expressly contained in them
and together they supersede any other such promises, warranties or representations. If there is any conflict between the Agreement and the Supplemental Release, the Supplemental Release shall take precedence and control. This Supplemental Release
may not be modified or amended except in a writing signed by both a duly authorized officer of Yahoo! and me. This Supplemental Release will bind the heirs, personal representatives, successors and assigns of both the Company and me, and inure to
the benefit of both the Company and me, our heirs, successors and assigns. If any provision of this Supplemental Release is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of
this Supplemental Release, and the provision in question will be modified by the court so as to be rendered enforceable. This Supplemental Release will be deemed to have been entered into and will be construed and enforced in accordance with the
laws of the state of California. 
 IF THIS SUPPLEMENTAL
RELEASE IS ACCEPTABLE TO YOU, PLEASE SIGN BELOW ON OR AFTER
THE SEPARATION DATE AND RETURN THE ORIGINAL TO DAVID WINDLEY
AT YAHOO!, 701 FIRST AVENUE, SUNNYVALE, CALIFORNIA 94089 BY 5:00 P.M. ON THE 21ST DAY AFTER YOUR SEPARATION DATE. 
 DO NOT SIGN THIS SUPPLEMENTAL RELEASE 
 BEFORE YOUR SEPARATION
DATE 
  

									
	By:	 	  
	 		 	Date:	 	  

		 	 Hilary Schneider
	 		 		 	
					
	cc:	 	 Personnel File

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]